Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%
HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

At a Glance

Live Snapshot
Market Cap$467.87M
EPS-1.4500
P/E Ratio-4.40
Earnings Date08/06/2026

rlmd

Sales/Maturities of Investments

Last Annual Value

35.69M

3-Year CAGR

-19%

5-Year CAGR

-25%

10-Year CAGR

%

Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Competitors Analysis of Sales/Maturities of Investments

RLMD · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
35.69M
-36.7%-26.7%N/A 
201.25M
115.9%N/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
145.00M
N/A69.9%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
40.00M
-18.2%47.7%1.4%
0.00
N/AN/AN/A
CLNN logo
Clene Inc.
NASDAQ:CLNN
0.00
N/AN/AN/A
0.00
N/AN/AN/A
110.87M
60.5%N/AN/A
0.00
N/AN/AN/A
154.39M
-6.8%N/AN/A
311.66M
-12.2%13.3%16.7%
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. Fair Value Envelope

RLMD · NASDAQ

Our analysis suggests that RLMD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.38, this represents a potential HIDDEN relative to our calculated worth for Relmada Therapeutics, Inc..

Intrinsic Value
Current Price: $6.38